IL1B and neoplasm: The total amount of IL-1β in the spleens, instead, was comparable in both STM-treated and untreated tumor-bearing mice, at day 10 and 30 PTI, and significantly increased in comparison to free-tumor mice (Figure 7D and Supplementary Figure S6).